Grifols (NASDAQ:GRFS) Shares Gap Down – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS) gapped down prior to trading on Thursday . The stock had previously closed at $7.40, but opened at $7.00. Grifols shares last traded at $7.15, with a volume of 362,744 shares traded.

Wall Street Analyst Weigh In

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Stock Performance

The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The firm’s fifty day moving average price is $7.66 and its 200 day moving average price is $8.19.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GRFS. GAMMA Investing LLC lifted its stake in shares of Grifols by 49.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 1,135 shares during the last quarter. R Squared Ltd bought a new position in Grifols during the fourth quarter valued at about $28,000. Signaturefd LLC lifted its position in shares of Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after buying an additional 2,153 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 4,970 shares in the last quarter. Finally, HighTower Advisors LLC increased its holdings in shares of Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,546 shares during the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.